Phase 4 N=160 Pecs II Block Versus Surgeon Infiltration for Open Subpectoral Biceps Tenodesis
Tendonitis
Primary: Opioid Utilization for the First 24 Hours After Surgery — 17.5; 20 morphine milligram equivalents
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=21 Visual Activity Evoked by Infrared in Humans After Dark Adaptation
Age Related Macular Degeneration · Retinitis Pigmentosa · Congenital Stationary Night Blindness
Primary: Visual Perception to Infrared: Mean Minimal Intensity (uW) at Which Participants Could See IR Between 900 - 1400 nm. — 0.671770454; 0.809204; 0.205456012; 0.222247 uW…
N/A N=54 Implicit Learning in Stroke Study
Stroke
Primary: Change in Modified Rivermead Mobility Index Score — 30.2; 34.4 score on a scale
N/A N=148 Randomized Comparison of Mindfulness Versus Group Support for Treatment of Low Sexual Desire in Women
Low Female Sexual Desire
Primary: Female Sexual Distress Scale-Revised (FSDS-R) — 22.88; 25.68; 23.02; 23.87 units on a scale
N/A N=165 Validation of a Diagnostic Algorithm of Giant Cell Arteritis
Giant Cell Arteritis
Primary: Number of CDU False-positive Patients — 73; 63; 0; 29 Participants
Phase 3 N=20 A Study of Lanadelumab (SHP643) in Chinese Participants With Hereditary Angioedema (HAE)
Hereditary Angioedema (HAE)
Primary: Number of Participants With Treatment-emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs) and Adverse Events of Special Interest (AESIs) — 15; 3; 1; 0…
Early Phase 1 N=12 A Microdose Evaluation Study of ABY-029 in Recurrent Glioma
Glioma
Primary: Fluorescence Signal Detection — 6.2; 5.0; 8.8 Biological variance ratio
N/A N=1,111 Helping Patients and Providers Make Better Decisions About Colorectal Cancer Screening
Cancer Screening Tests
Primary: Number of Participants Who Completed Colorectal Cancer Screening — 110; 95; 113; 113 Participants
Phase 1 N=32 Pharmacokinetic Study of Paracetamol UNIFLASH (125 MG/1.25 ML)
Acute Pain
Primary: Paracetamol Peak Plasma Concentration (Cmax) After Single Dose — 2181.04 ng/mL
N/A N=4,732 Safety of Pregnancy in BRCA Mutated Breast Cancer Patients
Breast Cancer
Primary: Disease-free Survival — 5.44; 5.45 DFS events/100*person-year
N/A N=1,000 Promoting CSD500 Use Among Women in Established Relationships
PSA · Unprotected Sex
Primary: Number of Female Participants With Positive PSA at 2-Month Visit — 18; 20 Participants
N/A N=190 Cumulative Pregnancy Rate With Lower and Higher Gonadotropin Dose During IVF Among Poor Responders
Infertility · Ovarian Dysfunction
Primary: Cumulative Clinical Pregnancy Rate — 27; 17 Participants
N/A N=60 Smokeless Tobacco Cessation Intervention for Firefighters
Smokeless Tobacco Cessation
Primary: Number of First Responders Recruited Who Completed a Screening Assessment — 163 Participants
N/A N=178 Evaluation of Providing Coffee to Patients Postoperatively to Decrease Length of Stay in the PACU
PACU Length of Stay · Postoperative Nausea · Postoperative Vomiting
Primary: PACU Length of Stay — 82; 76 minutes — p=0.12
N/A N=40 Building Adaptive Coping and Knowledge to Improve Daily Life
Sickle Cell Disease
Primary: Patient Reported Outcomes Measurement Information System (PROMIS) Pediatric Short Form Pain Interference Score — 61.5; 62.1; 58.2; 59.4 T-score